John B.A.G. Haanen

97.8k total citations · 18 hit papers
429 papers, 23.8k citations indexed

About

John B.A.G. Haanen is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John B.A.G. Haanen has authored 429 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 304 papers in Oncology, 168 papers in Immunology and 160 papers in Molecular Biology. Recurrent topics in John B.A.G. Haanen's work include Cancer Immunotherapy and Biomarkers (170 papers), CAR-T cell therapy research (160 papers) and Immunotherapy and Immune Responses (138 papers). John B.A.G. Haanen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (170 papers), CAR-T cell therapy research (160 papers) and Immunotherapy and Immune Responses (138 papers). John B.A.G. Haanen collaborates with scholars based in Netherlands, United States and United Kingdom. John B.A.G. Haanen's co-authors include Ton N. Schumacher, Christian U. Blank, Caroline Robert, James Larkin, Solange Peters, Karin Jordan, Franck Carbonnel, Hergen Spits, Keith M. Kerr and Carl G. Figdor and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

John B.A.G. Haanen

417 papers receiving 23.4k citations

Hit Papers

Management of toxicities ... 1991 2026 2002 2014 2017 1991 2018 2013 2022 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 1.7k citations John B.A.G. Haanen, James Larkin et al. Annals of Oncology profile →
  2. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.
    1991 1.7k citations John B.A.G. Haanen et al. profile →
  3. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
    2018 659 citations Alexander C. J. van Akkooi, John B.A.G. Haanen et al. profile →
  4. Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
    2013 624 citations John B.A.G. Haanen, Ton N. Schumacher et al. profile →
  5. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 565 citations John B.A.G. Haanen, James Larkin et al. Annals of Oncology profile →
  6. The “cancer immunogram”
    2016 540 citations Christian U. Blank, John B.A.G. Haanen et al. profile →
  7. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
    2014 527 citations Els M.E. Verdegaal, John B.A.G. Haanen et al. profile →
  8. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    2015 498 citations John B.A.G. Haanen et al. profile →
  9. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
    2014 427 citations Oscar Krijgsman, Paulien Cornelissen‐Steijger et al. profile →
  10. Skin-resident memory CD8 + T cells trigger a state of tissue-wide pathogen alert
    2014 415 citations Silvia Ariotti, Mirjam E. Hoekstra et al. profile →
  11. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
    2018 373 citations Emile E. Voest, John B.A.G. Haanen et al. profile →
  12. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
    2019 372 citations John B.A.G. Haanen, Christian U. Blank et al. Annals of Oncology profile →
  13. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
    2022 346 citations John B.A.G. Haanen et al. profile →
  14. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
    2018 306 citations Johannes V. van Thienen, Maureen J.B. Aarts et al. profile →
  15. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
    2021 195 citations Annegien Broeks, Christian U. Blank et al. profile →
  16. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
    2022 110 citations John B.A.G. Haanen et al. profile →
  17. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
    2024 57 citations Ton N. Schumacher, John B.A.G. Haanen et al. profile →
  18. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
    2024 40 citations Sara Balduzzi, Ton N. Schumacher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John B.A.G. Haanen Netherlands 72 13.9k 10.8k 6.8k 4.6k 2.0k 429 23.8k
Ignacio Melero Spain 88 15.8k 1.1× 16.8k 1.6× 6.6k 1.0× 3.0k 0.7× 2.4k 1.2× 396 28.2k
Glenn Dranoff United States 76 12.4k 0.9× 15.7k 1.4× 6.7k 1.0× 2.5k 0.5× 1.7k 0.8× 188 25.4k
James L. Gulley United States 71 11.7k 0.8× 8.3k 0.8× 4.2k 0.6× 5.7k 1.2× 1.8k 0.9× 568 18.4k
Matthew F. Krummel United States 65 11.2k 0.8× 17.8k 1.6× 6.4k 0.9× 2.9k 0.6× 1.9k 0.9× 162 27.4k
Mario Sznol United States 67 13.8k 1.0× 7.8k 0.7× 5.6k 0.8× 4.3k 0.9× 1.6k 0.8× 270 19.8k
Jennifer A. Wargo United States 68 15.9k 1.1× 8.2k 0.8× 11.4k 1.7× 3.6k 0.8× 2.9k 1.4× 263 25.5k
Alexander M.M. Eggermont Netherlands 72 18.5k 1.3× 6.7k 0.6× 9.4k 1.4× 3.1k 0.7× 2.7k 1.3× 389 25.8k
Elizabeth M. Jaffee United States 89 18.4k 1.3× 15.8k 1.5× 9.3k 1.4× 3.9k 0.8× 4.0k 2.0× 386 30.7k
Sara Y. Brucker Germany 31 18.4k 1.3× 9.1k 0.8× 7.2k 1.1× 6.6k 1.4× 4.9k 2.4× 130 27.9k
Thomas F. Gajewski United States 82 19.8k 1.4× 20.9k 1.9× 11.9k 1.8× 3.1k 0.7× 2.5k 1.2× 321 36.1k

Countries citing papers authored by John B.A.G. Haanen

Since Specialization
Citations

This map shows the geographic impact of John B.A.G. Haanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B.A.G. Haanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B.A.G. Haanen more than expected).

Fields of papers citing papers by John B.A.G. Haanen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B.A.G. Haanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B.A.G. Haanen. The network helps show where John B.A.G. Haanen may publish in the future.

Co-authorship network of co-authors of John B.A.G. Haanen

This figure shows the co-authorship network connecting the top 25 collaborators of John B.A.G. Haanen. A scholar is included among the top collaborators of John B.A.G. Haanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John B.A.G. Haanen. John B.A.G. Haanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nijenhuis, Cynthia M., Inge Jedema, Justin T. Moyers, et al.. (2025). Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products. Transplantation and Cellular Therapy. 31(3). S610–S625. 3 indexed citations
2.
Borgers, Jessica S.W., Kyra A. Gelderman, Theo Rispens, et al.. (2024). Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for ImmunoTherapy of Cancer. 12(6). e009215–e009215. 8 indexed citations
3.
Eertwegh, Alfons J.M. van den, John B.A.G. Haanen, Rozemarijn S. van Rijn, et al.. (2024). BRAF/MEK inhibitor rechallenge in advanced melanoma patients. Cancer. 130(9). 1673–1683. 5 indexed citations
4.
Brugarolas, James, Pooja Ghatalia, S. George, et al.. (2023). 1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Annals of Oncology. 34. S1011–S1011. 4 indexed citations
5.
Voorwerk, Leonie, Sara Balduzzi, Roberto Salgado, et al.. (2023). Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial. The Breast. 70. 76–81. 15 indexed citations
6.
7.
Hoeijmakers, Lianne, Marta López‐Yurda, Lindsay G. Grijpink-Ongering, et al.. (2023). 1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial. Annals of Oncology. 34. S670–S670. 1 indexed citations
8.
Zeijl, Michiel C.T. van, Liesbeth C. de Wreede, Michel W.J.M. Wouters, et al.. (2023). Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands. Journal of Immunotherapy. 46(5). 197–204. 8 indexed citations
9.
Borgers, Jessica S.W., Elisabeth M. Terveer, Monique E. van Leerdam, et al.. (2022). Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial. BMC Cancer. 22(1). 1366–1366. 18 indexed citations
10.
Hiel, Bernies van der, Else A. Aalbersberg, Maurits Wondergem, et al.. (2022). 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients. Clinical Nuclear Medicine. 47(7). 583–589. 7 indexed citations
11.
Jarosch, Sebastian, Jack Barton, Simon Grassmann, et al.. (2022). Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. Science Immunology. 7(74). eabm2077–eabm2077. 15 indexed citations
12.
Eertwegh, Alfonsus Johannes Maria van den, Liesbeth C. de Wreede, Doranne L. Hilarius, et al.. (2021). Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers. 13(20). 5077–5077. 2 indexed citations
13.
14.
Leeneman, B, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, et al.. (2020). Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers. 12(4). 1003–1003. 12 indexed citations
15.
Haanen, John B.A.G., et al.. (2020). BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA. Retinal Cases & Brief Reports. 16(4). 430–434. 10 indexed citations
16.
Bakker, Noor A. M., Renate de Boer, Corinne Marie, et al.. (2019). Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. Journal of Biotechnology. 306. 100007–100007. 13 indexed citations
17.
18.
Dijk, Elon H. C. van, Carla M.L. van Herpen, Marina Marinkovic, et al.. (2015). Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. Ophthalmology. 122(9). 1907–1916. 58 indexed citations
19.
Kemper, Kristel, Oscar Krijgsman, Paulien Cornelissen‐Steijger, et al.. (2015). Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts. EMBO Molecular Medicine. 7(9). 1104–1118. 103 indexed citations
20.
Ariotti, Silvia, Joost B. Beltman, Grzegorz Chodaczek, et al.. (2012). Tissue-resident memory CD8 + T cells continuously patrol skin epithelia to quickly recognize local antigen. Proceedings of the National Academy of Sciences. 109(48). 19739–19744. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ignacio Melero Breakdown of academic impact, for papers by Glenn Dranoff Breakdown of academic impact, for papers by James L. Gulley Breakdown of academic impact, for papers by Matthew F. Krummel Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Jennifer A. Wargo Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by Elizabeth M. Jaffee Breakdown of academic impact, for papers by Sara Y. Brucker Breakdown of academic impact, for papers by Thomas F. Gajewski
Rankless by CCL
2026